• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack

    1/26/26 10:13:47 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCY alert in real time by email

    VANCOUVER, British Columbia, Jan. 26, 2026 (GLOBE NEWSWIRE) --  Equity Insider Market Intelligence Brief –

    The global market has entered a cycle of defensive hardening.

    After a decade of aggressive speculation, the defining theme of 2026 is Resilience. Investors are realizing that the systems powering the modern world—from the energy grid to the human body—are dangerously fragile.

    The "Everything Bubble" ignored physical and biological reality. Now reality is repricing the market.

    Capital is rotating into the "Sovereign Stack": the critical minerals that cannot be substituted, the supply chains that must be domesticated, and the biological technologies that extend the lifespan of the workforce.

    The companies profiled below are not selling convenience. They are selling survival.

    They own the tungsten for the missiles, the fluorspar for the steel, the gold for the vault, and the cellular tech to repair the human machine. This is the Resilience Doctrine.

    THE BIOLOGICAL INFRASTRUCTURE

    Avant Technologies Inc. (OTCQB:AVAI) has executed a decisive pivot into regenerative medicine, targeting the most critical vulnerability in the modern economy: the biological collapse of the human workforce.

    While the market obsesses over upgrading the digital grid, Avant is upgrading the human operator.

    Chronic disease and accelerated aging are the rust of the labor force. Avant is building the anti-corrosion layer.

    The transformation began on November 4, with the formation of Insulinova, a joint venture designed to functionally restore insulin production in diabetics. This is not management. This is restoration.

    Two weeks later, on November 18, the company secured an exclusive license for Klotho-producing cells. Klotho is the longevity protein, the biological marker that declines with age and correlates directly with organ deterioration and mortality risk.

    The thesis is blunt: A nation cannot compete if its population is sick. Avant is positioning itself as the primary engineer of biological resilience, delivering the cellular upgrades required to sustain a high-performance economy.

    Read this and more news for Avant at: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/  

    THE CLINICAL SIGNAL

    Oncolytics Biotech Inc. (NASDAQ:ONCY) continues to validate its role as the universal key for gastrointestinal oncology, recently releasing updated clinical data showing significant activity in third-line metastatic anal cancer.

    This is the resilience of the biological supply chain.

    Standard immunotherapies—the multi-billion dollar checkpoint inhibitors—fail in GI cancers because the tumors are cold. Invisible to the immune system. Oncolytics' lead asset, pelareorep, uncloaks them.

    On December 16, the company reported a 33% response rate in colorectal cancer, a tumor type where immunotherapy traditionally delivers single-digit activity. The January 12 anal cancer data confirms the pattern. The mechanism is reproducible.

    The scientific elite have taken notice. On January 7, the company expanded its Scientific Advisory Board with heavyweights from Memorial Sloan Kettering. This is not protocol design. This is registration preparation.

    In a market starving for assets that can extend the patent life of Big Pharma's blockbusters, Oncolytics is securing the most valuable commodity in biotech: survival data in untreatable patients.

    Read this and more news for Oncolytics Biotech at: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/

    THE SUPPLY CHAIN ANCHOR

    Ares Strategic Mining Inc. (CSE:ARS) (OTCQB:ARSMF) is solving a zero-sum vulnerability in the American industrial base, recently issuing a construction update confirming that underground infrastructure at its Lost Sheep Mine is complete.

    The United States imports 100% of its fluorspar. Without it, you cannot produce aluminum, high-grade steel, or lithium-ion batteries.

    Ares is building the only permitted domestic source of this critical mineral.

    This is not a drill program. It is an extraction timeline. With ventilation systems operational and mining equipment mobilized, Ares is transitioning from development to production.

    The geopolitical context is stark. China controls 60% of global fluorspar supply. Mexico provides the remainder of U.S. imports. Any disruption in those supply chains halts domestic manufacturing.

    Ares is repatriating the supply chain. The Lost Sheep deposit in Utah contains high-grade fluorspar in a jurisdiction with zero permitting risk. The mine is built. The infrastructure is complete. The timeline to first production is measured in quarters.

    In the Resilience Economy, owning the raw materials of industry is the only hedge against geopolitical coercion. Ares is turning a strategic weakness into a sovereign asset.

    Read this and more news for Ares at: https://equity-insider.com/2026/01/20/the-glitch-dod-awards-169m-to-stock-trading-under-110m/

    THE GEOPOLITICAL ANCHOR

    Rua Gold (TSXV:RUA) (OTCQB:NZAUF) is positioning itself at the intersection of monetary safety and defense necessity, recently engaging ICP Securities for automated market making services as it advances its flagship Reefton Goldfield project in New Zealand.

    While the market values Rua for its control of a historic district that produced over 2 million ounces of high-grade gold, the Resilience trade sees a second asset: Antimony.

    The Reefton system is rich in stibnite, the primary ore for antimony. This is a critical defense mineral essential for munitions, night vision technology, and flame retardants.

    China controls global antimony supply and recently restricted exports. The West is scrambling for secure, non-adversarial sources.

    Rua Gold offers a dual-threat hedge: High-grade gold to protect against currency debasement, and strategic antimony to protect against supply chain weaponization. The company is not just exploring. It is repatriating defense infrastructure.

    Read this and more news for RUA Gold at:

    https://equity-insider.com/2025/04/24/others-found-1911-g-t-here-before-now-a-proven-11b-mining-team-is-back-to-finish-the-job/

    THE SILVER INVENTORY

    Rush Gold Corp. (CSE:RGN) announced the completion of Phase 1 geologic reconnaissance at its Legal Tender and Skylight properties, validating a strategic inventory of high-grade silver in Nevada.

    In the 2026 economy, silver is the conductive backbone of the power grid and the electronics sector. Every solar panel, EV charger, and data center requires it. The metal cannot be recycled at scale. It cannot be substituted.

    Rush Gold is ground-truthing a system that has historically returned grades as high as 1,875 grams per tonne silver. These are not trace anomalies. These are economic intercepts.

    The arbitrage is acute. The market views Rush as a generic explorer. The data suggests it holds industrial-grade inventory in the world's premier mining jurisdiction.

    As industrial demand for silver accelerates alongside monetary demand for gold, Rush Gold provides exposure to the Devil's Metal in a safe harbor. They are not just looking for ounces. They are verifying a strategic stockpile.

    The Resilience Doctrine is complete: Biological infrastructure, clinical proof, industrial minerals, monetary metals, and defense materials. This is the Sovereign Stack.

    Read this and more news for Rush Gold news at:

    https://equity-insider.com/2025/09/30/the-nevada-gold-story-hiding-in-plain-sight/

    CONTACT:

    Equity Insider

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. Specifically, readers should be aware that Avant Technologies Inc., Oncolytics Biotech Inc., Ares Strategic Mining Inc., RUA Gold Inc., and Rush Gold Corp. are or have directly/indirectly been commercial clients of MIQ, Baystreet.ca Media Corp. ("BAY"), or their affiliates (entities under common ownership). The owner/operator of MIQ own shares of Avant Technologies Inc., Oncolytics Biotech Inc., Ares Strategic Mining Inc., and Rush Gold Corp. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of these companies at any time without any further notice commencing immediately and ongoing. The owner/operator of MIQ does not own any shares of RUA Gold Inc. but reserves the right to buy and sell shares of RUA Gold Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Avant Technologies Inc. Technical information relating to RUA Gold Inc. has been reviewed and approved by Simon Henderson, CP, AUSIMM, a Qualified Person as defined by National Instrument 43-101. Mr. Henderson is Chief Operational Officer of RUA Gold Inc., and therefore is not independent of the Company. The scientific and technical information disclosed in this document relating to Rush Gold Corp. have been reviewed and approved by Qualified Person (QP), Kristopher J. Raffle, P.Geo. Regarding Avant Technologies Inc., Oncolytics Biotech Inc., Ares Strategic Mining Inc., RUA Gold Inc., and Rush Gold Corp., while the technical information contained herein is derived from official regulatory filings and news releases previously approved by the issuers' designated Qualified Persons, this specific publication has not been independently reviewed, verified, or approved by those issuers. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.



    Primary Logo

    Get the next $ONCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCY

    DatePrice TargetRatingAnalyst
    8/13/2025$7.00Buy
    Lake Street
    10/6/2022$3.00Buy
    Maxim Group
    More analyst ratings

    $ONCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Oncolytics Biotech with a new price target

    Lake Street initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $7.00

    8/13/25 8:42:12 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Oncolytics Biotech with a new price target

    Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00

    10/6/22 9:22:17 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Oncolytics Biotech with a new price target

    H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00

    2/17/21 2:20:07 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seizinger Bernd R. bought $103,770 worth of shares (100,000 units at $1.04), increasing direct ownership by 27% to 466,991 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/20/26 4:30:18 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC., Jan. 28, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – As the global oncology clinical trials market surges toward a projected $25.61 billion valuation by 2035[1], a structural rotation is favoring 'registration-ready' platforms that demonstrate exceptional efficacy and pivotal-trial alignment with 2026's evolving FDA regulatory frameworks[2]. Investors are increasingly prioritizing late-stage and newly commercial companies poised for rapid maturation as sector fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ:ONCY), BioNTech (NASDAQ:BNTX), MAIA Biotechnology (NYSE-A: MAIA)

    1/28/26 9:15:00 AM ET
    $ACRV
    $BNTX
    $IBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery assets[1]. With the FDA's accelerated approval pathway delivering survival wins across 65% of solid tumor indications, the 2026 regulatory landscape is demanding a new breed of registration-directed study designs that prioritize raw objective response rates and durability[2]. This structural shift creates an asymmetric investment window for Oncolytic

    1/27/26 10:50:00 AM ET
    $CHRS
    $MRK
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack

    VANCOUVER, British Columbia, Jan. 26, 2026 (GLOBE NEWSWIRE) --  Equity Insider Market Intelligence Brief – The global market has entered a cycle of defensive hardening. After a decade of aggressive speculation, the defining theme of 2026 is Resilience. Investors are realizing that the systems powering the modern world—from the energy grid to the human body—are dangerously fragile. The "Everything Bubble" ignored physical and biological reality. Now reality is repricing the market. Capital is rotating into the "Sovereign Stack": the critical minerals that cannot be substituted, the supply chains that must be domesticated, and the biological technologies that extend the lifespan of the w

    1/26/26 10:13:47 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Seizinger Bernd R. bought $103,770 worth of shares (100,000 units at $1.04), increasing direct ownership by 27% to 466,991 units (SEC Form 4)

    4 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/20/26 4:30:18 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Kelly Jared claimed ownership of 73,900 shares (SEC Form 3)

    3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/2/26 4:30:39 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Andrews Patricia S claimed ownership of 42,728 shares (SEC Form 3)

    3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

    1/2/26 4:30:41 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    SEC Filings

    View All

    Oncolytics Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    1/15/26 4:21:34 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    1/14/26 6:10:26 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

    1/12/26 4:05:33 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

    SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br

    1/14/26 9:00:00 AM ET
    $CGON
    $ONCY
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

    New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep's development as a platform immunotherapy across GI tumors Company continues to strengthen its clinical and strategic foundation to advance registration-enabling studies in high-value indications Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal ("GI") Tumor Scientific Advisory Board ("SAB") with the appointment of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris, three globally recognized experts in gastrointestinal oncology. The GI SAB was recent

    1/7/26 9:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCY
    Financials

    Live finance-specific insights

    View All

    Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

    Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareo

    8/8/25 9:05:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

    American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first qu

    5/14/25 4:01:00 PM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

    Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

    5/6/25 7:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care